DMN:FRA
Diamyd Medical AB
၀.၀၆၃ €
၀.၀၀%
(၀.၀၀) 1D
နို ၁၆, GMT+၁ ၀၈:၀၉:၂၇ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
၀.၀၆ €
High
၀.၀၆ €
Low
၀.၀၆ €
Mkt. cap
၁၃.၅၀ ကုဋေ
Avg. vol.
၀.၀၀
Volume
၀.၀၀
52-wk high
၁.၈၀ €
52-wk low
၀.၀၅ €
No. of employees
၄၂
Open
၀.၀၆ €
High
၀.၀၆ €
Low
၀.၀၆ €
Mkt. cap
၁၃.၅၀ ကုဋေ
Avg. vol.
၀.၀၀
Volume
၀.၀၀
52-wk high
၁.၈၀ €
52-wk low
၀.၀၅ €
No. of employees
၄၂
News stories
From web sources and news partners
Business Insider
·
ပြီးခဲ့သည့် ၄၈ မိနစ်
A veteran strategist sees a split in the stock market leading to a 15% drop in the S&P 500
Reuters
·
ပြီးခဲ့သည့် ၁၉ မိနစ်
S&P 500, Nasdaq futures slide as Nvidia earnings, Anthropic debut loom
Benzinga
·
ပြီးခဲ့သည့် ၁ နာရီ
Stock Market Today: Dow Jones, S&P 500 Futures Trade Mixed as Scott Bessent Presses Nvidia Over China Chi
Traders Union
·
ပြီးခဲ့သည့် ၃၃ မိနစ်
S&P 500 remained close to all-time highs after Nasdaq's drop, Dario Perkins notes
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB